BioWorld Asia

Sep. 16, 2009

Alcon Paying Up to $589M for EsbaTech Eye Business

Underlining the current vogue for antibody-based technologies, Alcon Inc. is acquiring the ophthalmology business of ESBATech AG for $150 million in cash plus up to $439 million in potential milestones. (BioWorld International) Read More

ArGEN-X Snares $13.8M for Llama-based Antibody Platform

Differentiation Control Switch Sheds Light on Cancer Triggers

Troubled Arpida's Stock Surges as Evolva Rides to the Rescue

Antisoma Faces Good Problem; Hiring for 2 Potential Launches

Mutabilis Spins Out a FAB Company for MRSA Work

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 13, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

HX-16108 holds promise for treating inflammatory skin diseases

BioWorld Science

Atopic dermatitis (AD) is an inflammatory skin disease accompanied by pruritus, for which IL-13 and IL-31 are clinically validated targets. Earendil Labs Inc. has...